In our study, we validated the increase in expression of LSD1 during the progression of cervical cancer and confirmed the enhanced therapeutic effect against cervical cancer when combining CD47/PD-L1 blockade therapy with an LSD1 inhibitor. Here, CD47 is linked to cervical carcinoma.